Chromoendoscopy for Dysplasia Detection in Chronic Inflammatory Bowel Disease
Launched by KAROLINSKA UNIVERSITY HOSPITAL · Jan 4, 2012
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
Background: Patients with ulcerative colitis and Crohn's colitis are at increased risk of colon cancer. The usefulness of chromoendoscopy is debated. Previous studies are either based on magnifying endoscopy or on non-randomized trials. Some guidelines recommend chromoendoscopy with targeted biopsies and some normal colonoscopy with up to 40 random biopsies.
Chromoendoscopy has the ability to identify subtle lesions that are otherwise missed by standard endoscopy. Whether chromoendoscopy with targeted biopsies can replace standard colonoscopy with random biopsies in the surveillance of pat...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients with ulcerative colitis or Crohn's colitis satisfying criteria for surveillance colonoscopy:
- • Ulcerative colitis, extensive \> 8 years OR Crohn's colitis involving ≥ 1/3 of colon/rectum
- • history of PSC or
- • history of previous dysplasia on colon biopsies or
- • family history of colon cancer in first degree relative
- Exclusion Criteria:
- • Patients who decline to participate
- • Unable to give informed consent
- • Increased risk of bleeding (i.e. Warfarin, bleeding disorders, Clopidogrel)
About Karolinska University Hospital
Karolinska University Hospital is a leading academic medical center in Sweden, renowned for its commitment to advanced healthcare research and innovative clinical practices. As a key sponsor of clinical trials, the hospital leverages its extensive expertise in medical research and collaboration with Karolinska Institutet, one of the world's foremost medical universities. The institution is dedicated to enhancing patient care through rigorous scientific investigation, focusing on a wide range of therapeutic areas. With a multidisciplinary approach and a strong emphasis on translational medicine, Karolinska University Hospital aims to bridge the gap between laboratory findings and clinical application, ultimately striving to improve health outcomes and advance medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Peter T Schmidt, MD, PhD
Principal Investigator
Karolinska University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials